

PATIENT ENGAGEMENT IN 2030

How can **patient engagement** contribute towards building a **new ecosystem** for drug development & therapy?

Patient engagement has become a key element in drug development during recent years and will only become more important as time goes on. At the same time, these processes are undergoing change towards a new ecosystem. By taking the lessons learned from the past, taking current initiatives and bright ideas for the future, patient engagement plays a crucial role in the future of drug development & therapy.



On June 9th 2022, admedicum will organize an event in collaboration with HollandBIO and where patient representatives will set the scene and subsequently multiple stakeholder speakers will share perspectives towards solutions, improvements and opportunities for patient engagement in 2030. The different perspectives will be followed by an interactive and open 'parliamentary style' debate.

Sharing knowledge & networking

Meet up with people in person!

All necessary and mandatory COVID-19 measures will be fully implemented with special attention for attendees falling in a higher-risk category.

Practical info

9 June 2022

14:00 doors open, 14:45 program, 17:30 drinks
Muntgebouw, Leidseweg 9, Utrecht,
the Netherlands



admedicum

Business for Patients



Free registration here: <https://bit.ly/34o3h7c>

PATIENT ENGAGEMENT IN 2030

How can **patient engagement** contribute towards building a **new ecosystem** for drug development & therapy?

Program

- 14:00 – 14:45** **Registration**
Coffee-tea / refreshments
- 14:45 – 14:50** **Welcome**
Philipp von Gallwitz, Co-Founder admedicum
- 14:50 – 15:20** **Keynote - Nicola Bedlington, former Secretary General European Patient' Forum**
How to achieve structured systematic ethical patient engagement by 2030. The role of patient engagement in the life cycle of medicines (e.g. PFDD, PARADIGM initiative, patient education).
- 15:20 – 16:00** **Solutions / improvements / opportunities for patient engagement during the drug development phase and after market entry from different stakeholder perspectives (part 1)**
- 15:20 – 15:40 Regulatory perspective by Cécile Ollivier, OCM Director - Regulatory Science EU Critical Path Institute (C-Path)
- 15:40 – 16:00 Patient community driven alliances by Ana Mingorance, Chief Development Officer (Loulou Foundation)
- 16:00 – 16:20** **Break**
Coffee & tea / water
- 16:20 – 17:00** **Solutions / improvements / opportunities for patient engagement during the drug development phase and after market entry from different stakeholder perspectives (part 2)**
- 16:20 – 16:40 Industry perspective drug development phase by Annamarie Dillon, Senior Director Patient Advocacy (Orchard Therapeutics)
- 16:40 – 17:00 Industry perspective market access phase by Joep Rijnierse, Medical Director (Amgen Nederland)
- 17:00 – 17:30** **Parliamentary debate**
Moderated by Roger Legtenberg, Senior Partner & Head of Benelux Region admedicum
- 17.30 – 18:30** **Networking**
Drinks & dinner snacks

N.B.: Focus of complete event should be positive towards solutions and not looking back negatively.

Join us!

Free registration here: <https://bit.ly/34o3h7c>

admedicum
Business for Patients



insmed